Author:
Kim Jason S.,Borges Silvana,Clauw Daniel J.,Conaghan Philip G.,Felson David T.,Fleming Thomas R.,Glaser Rachel,Hart Elizabeth,Hochberg Marc,Kim Yura,Kraus Virginia B.,Lapteva Larissa,Li Xiaojuan,Majumdar Sharmila,McAlindon Timothy E.,Mobasheri Ali,Neogi Tuhina,Roemer Frank W.,Rothwell Rebecca,Shibuya Robert,Siegel Jeffrey,Simon Lee S.,Spindler Kurt P.,Nikolov Nikolay P.
Funder
U.S. Food and Drug Administration
Arthritis Foundation
Subject
Anesthesiology and Pain Medicine,Rheumatology
Reference91 articles.
1. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis;Kraus;Osteoarthr Cartil,2011
2. Value of biomarkers in osteoarthritis: current status and perspectives;Lotz;Ann Rheum Dis,2013
3. Osteoarthritis is a serious disease;Hawker;Clin Exp Rheumatol,2019
4. 21st Century Cures Act, FDA website: 2020. [Accessed 1 June 2022].
5. FDA-Arthritis Foundation osteoarthritis drug development workshop: assessment of long-term benefit, https://www.fda.gov/drugs/news-events-human-drugs/fda-arthritis-foundation-osteoarthritis-drug-development-workshop-assessment-long-term-benefit (2021).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献